Lantern Pharma (LTRN) vs Phio Pharmaceuticals (PHIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Phio Pharmaceuticals (PHIO) has outperformed Lantern Pharma (LTRN) over the past year, losing 59.8% versus a loss of 81.9%. Over five years, LTRN leads with a -91.7% price change compared with -99.5% for PHIO. Lantern Pharma is the larger company by market cap ($12.1 million vs $11.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LTRN | PHIO |
|---|---|---|
| Share price | $0.8127 | $0.9788 |
| Market cap | $12.14M | $11.37M |
| 1-day change | -2.08% | -1.11% |
| YTD return | -72.61% | -7.32% |
| 1-year return | -81.92% | -59.79% |
| 5-year return | -91.71% | -99.46% |
| EPS (TTM) | $-1.63 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.68 | $4.19 |
| 52-week low | $0.7603 | $0.813 |
| Distance from 52-week high | -82.63% | -76.64% |
| Analyst consensus | none | none |
| Avg. price target upside | +2053.32% | +1330.32% |
| Average volume | 180.42K | 582.32K |
| Shares outstanding | 14.94M | 11.62M |
| Employees | 16 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHIO has outperformed LTRN by 22.1 percentage points over the past year.
About Lantern Pharma
LTRN stock →Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Phio Pharmaceuticals
PHIO stock →Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
LTRN vs PHIO FAQ
Which is bigger, Lantern Pharma or Phio Pharmaceuticals?
Lantern Pharma (LTRN) is larger, with a market capitalization of $12.14M compared with $11.37M for Phio Pharmaceuticals (PHIO).
Which stock has performed better over the past year, LTRN or PHIO?
PHIO returned -59.79% over the past 12 months, compared with -81.92% for LTRN (price return, excluding dividends). Past performance does not predict future results.
Are Lantern Pharma and Phio Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.